Clinical Trial Update: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation study of APG-1387 in combination with toripalimab in advanced solid tumors has been terminated after Phase 1/Phase 2 evaluation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• APG-1387 (APG-1387)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED